D010091Chemicals & DrugsD02.092.570.665881760.885117OximesFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentDivisionvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonEndocrine Neoplasia & HDInvestigational Cancer TherapeuticsMelanoma Medical OncologyMD AndersonVIVEKSUBBIAHVIVEK SUBBIAH9518SUBBIAH, VIVEKAssistant ProfessorMARIA ECABANILLASMARIA E CABANILLAS8975CABANILLAS, MARIA EAssociate ProfessorMICHAEL ADAVIESMICHAEL A DAVIES8753DAVIES, MICHAEL AAssociate Professor10Assistant Professor14Associate Professor32Clinical InstructorHUSSEINTAWBIHUSSEIN TAWBI11940TAWBI, HUSSEINAssociate Professor2.048330.0071668188research area of0.8756040.026927384subject area forJOHNKIRKWOODJOHN KIRKWOOD0.000000000000000.000000000000005674KIRKWOOD, JOHNClinical InstructorDepartment of Family and Community MedicineFamily & Community MedicineBaylor College of Medicine32877599Dummer R, Hauschild A, Santinami M, Atkinson V, Mandal? M, Kirkwood JM, Chiarion Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Gasal E, Tan M, Long GV, Schadendorf DThe New England journal of medicineFive-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2020 09 17; 383(12):1139-1148.N Engl J Med2020-09-02T00:00:002020Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.33020648Dummer R, Lebb? C, Atkinson V, Mandal? M, Nathan PD, Arance A, Richtig E, Yamazaki N, Robert C, Schadendorf D, Tawbi HA, Ascierto PA, Ribas A, Flaherty KT, Pakhle N, Campbell CD, Gusenleitner D, Masood A, Brase JC, Gasal E, Long GVNature medicineCombined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. Nat Med. 2020 10; 26(10):1557-1563.Nat Med2020-10-05T00:00:002020Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.33872566Stocks B, Fuentes H, McDowell Z, Brooks M, Jones JAThe Canadian journal of urologyOncogene targeted therapy for metastatic primary scrotal melanoma. Can J Urol. 2021 04; 28(2):10643-10647.Can J Urol2021-04-01T00:00:002021Oncogene targeted therapy for metastatic primary scrotal melanoma.34225229Schadendorf D, Robert C, Dummer R, Flaherty KT, Tawbi HA, Menzies AM, Banerjee H, Lau M, Long GVEuropean journal of cancer (Oxford, England : 1990)Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers. Eur J Cancer. 2021 08; 153:234-241.Eur J Cancer2021-07-02T00:00:002021Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers.34996063Salek M, Oak N, Hines M, Maciaszek JL, Tatevossian R, Sharma A, Nichols KE, Campbell PBlood advancesDevelopment of BRAFV600E-positive acute myeloid leukemia in a patient on long-term dabrafenib for multisystem LCH. Blood Adv. 2022 04 26; 6(8):2681-2684.Blood Adv2022-04-26T00:00:002022Development of BRAFV600E-positive acute myeloid leukemia in a patient on long-term dabrafenib for multisystem LCH.true1Clinical InstructorClinical Instructortrue1Associate ProfessorAssociate Professortrue1Assistant ProfessorAssistant Professortrue1Associate ProfessorAssociate Professortrue1Associate ProfessorAssociate Professor